Targeting sex steroid biosynthesis for breast and prostate cancer therapy
M Poutanen, M Hagberg Thulin, P Härkönen - Nature Reviews Cancer, 2023 - nature.com
Sex steroids are major promoters of the growth of breast and prostate cancers. This Review
by Poutanen et al. describes the development of treatments for these cancer types that act to …
by Poutanen et al. describes the development of treatments for these cancer types that act to …
Evolution of androgen deprivation therapy (ADT) and its new emerging modalities in prostate cancer: an update for practicing urologists, clinicians and medical …
E Choi, J Buie, J Camacho, P Sharma… - Research and reports …, 2022 - Taylor & Francis
Androgen deprivation therapy (ADT) has been the main management strategy for prostate
cancer for more than eight decades, nowadays achieved commonly by administration of …
cancer for more than eight decades, nowadays achieved commonly by administration of …
Discovery of ARD-2051 as a potent and orally efficacious proteolysis targeting chimera (PROTAC) degrader of androgen receptor for the treatment of advanced …
We report the discovery of ARD-2051 as a potent and orally efficacious androgen receptor
(AR) proteolysis-targeting chimera degrader. ARD-2051 achieves DC50 values of 0.6 nM …
(AR) proteolysis-targeting chimera degrader. ARD-2051 achieves DC50 values of 0.6 nM …
Treatment landscape for patients with castration-resistant prostate cancer: patient selection and unmet clinical needs
F Turco, S Gillessen, R Cathomas… - Research and reports …, 2022 - Taylor & Francis
Metastatic castration resistant prostate cancer (CRPC) is an inevitably fatal disease.
However, in recent years, several treatments have been shown to improve the outcome of …
However, in recent years, several treatments have been shown to improve the outcome of …
Targeted α-therapy using astatine (211At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compound
T Watabe, K Kaneda-Nakashima, Y Shirakami… - European Journal of …, 2023 - Springer
Purpose Targeted α-therapy (TAT) for prostate-specific membrane antigen (PSMA) is a
promising treatment for metastatic castration-resistant prostate cancer (CRPC). Astatine is …
promising treatment for metastatic castration-resistant prostate cancer (CRPC). Astatine is …
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate …
Background The most recent overall survival (OS) and adverse event (AE) data have not
been compared for the three guideline-recommended high-risk non-metastatic castration …
been compared for the three guideline-recommended high-risk non-metastatic castration …
Machine learning and artificial intelligence: a paradigm shift in big data-driven drug design and discovery
P Pasrija, P Jha, P Upadhyaya… - Current Topics in …, 2022 - benthamdirect.com
Background: The lengthy and expensive process of developing a novel medicine often takes
many years and entails a significant financial burden due to its poor success rate …
many years and entails a significant financial burden due to its poor success rate …
Overall survival after systemic treatment in high-volume versus low-volume metastatic hormone-sensitive prostate cancer: systematic review and network meta …
Context Novel prospective randomized controlled observations addressing combination
therapy in metastatic hormone-sensitive prostate cancer (mHSPC) have demonstrated …
therapy in metastatic hormone-sensitive prostate cancer (mHSPC) have demonstrated …
Nonmetastatic castration-resistant prostate cancer: current challenges and trends
A Figueiredo, L Costa, MJ Maurício, L Figueira… - Clinical Drug …, 2022 - Springer
Prostate carcinoma is a highly prevalent biologically and clinically diverse disease,
generally associated with a consistent elevation of prostate-specific antigen levels …
generally associated with a consistent elevation of prostate-specific antigen levels …
Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review
Background and objective Recently, research on treatment intensification has gathered
momentum, and three novel therapy combinations were approved for metastatic castration …
momentum, and three novel therapy combinations were approved for metastatic castration …